Aclid – a security and compliance automation platform for the biotechnology industry – recently announced it closed an oversubscribed seed financing of $3.3 million. This funding round led by 2048 Ventures and IA Ventures will enable Aclid to meet customer demand for its real-time screening and verification platform.
In July 2023, Senator Ed Markey (D-MA) and Representative Anna Eshoo (CA-16) introduced the Securing Gene Synthesis Act, which mandates DNA synthesis providers to comply with screening regulations. And separately, the Department of Health and Human Services (HHS) is strengthening the 2010 Screening Framework Guidance for Providers of Synthetic Double-Stranded DNA to cover oligonucleotides and gene synthesis equipment, including bench-top DNA synthesizers.
Aclid was launched by Columbia University Professor of Systems Biology Harris Wang, Ph.D., and Kevin Flyangolts. This combines their synthetic biology and engineering backgrounds, they formed Aclid to make genetic engineering safer.
KEY QUOTES:
“Before Aclid, DNA synthesis providers struggled with error-prone, time-consuming, and expensive manual approaches to biosecurity and compliance. We knew we could make an automated product that is simple to deploy, keeps security teams focused on the most important risks, and always up-to-date with the latest regulations. Gene synthesis providers using our solution already spend less time reviewing orders and managing compliance. We’re excited to have the support of 2048 Ventures, IA Ventures, and our advisors to help secure DNA synthesis, the foundation of the bioeconomy. “
— Kevin Flyangolts, Aclid Founder and Chief Executive Officer
“DNA synthesis is rapidly growing and decentralizing – a great step toward building a better future with biology. As the industry grows, we must ensure that this critical technology is used for the benefit of humanity. Aclid’s biosecurity platform ensures the safe and rapid growth of the bioeconomy.”
— Julie Wolf, Ph.D., principal at 2048 Ventures
“In the 13 years since the release of the first DNA screening guidelines, security, and compliance have never been more important or more challenging for the gene synthesis industry. By automating the most time-consuming parts of the process – customer verifications and follow-up – Aclid makes it easy for gene synthesis providers to stay compliant.”
— Harris Wang, Ph.D., Aclid Scientific Founder
